Especially for indications with significant TATs, such as Trastuzumab Emtansine and Trastuzumab Deruxtecan targeting ERBB2, the prognosis and quality of life of ERBB2-positive breast cancer patients have been improved (Díaz-Rodríguez et al., 2021). Here, ERBB2 is linked to breast cancer.